FGF23 functions and disease.
Journal
Minerva endocrinology
ISSN: 2724-6116
Titre abrégé: Minerva Endocrinol (Torino)
Pays: Italy
ID NLM: 101777342
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
pubmed:
2
4
2021
medline:
6
1
2023
entrez:
1
4
2021
Statut:
ppublish
Résumé
The main function of fibroblast growth factor 23 (FGF23) is the regulation of phosphate metabolism through its action on the sodium-dependent phosphate cotransporters in the proximal renal tubules. Additionally, FGF23 interacts with vitamin D and parathyroid hormone in a complex metabolic pathway whose detailed mechanisms are still not clear in human physiology and disease. More recently, research has also focused on the understanding of mechanisms of FGF23 action on organs and system other than the kidneys and bone, as well as on its interaction with other metabolic pathways. Collectively, the new evidence are successfully used for the clinical evaluation and management of FGF23-related disorders, for which new therapies with many potential applications are now available.
Identifiants
pubmed: 33792238
pii: S2724-6507.21.03378-2
doi: 10.23736/S2724-6507.21.03378-2
doi:
Substances chimiques
Fibroblast Growth Factors
62031-54-3
Parathyroid Hormone
0
Phosphates
0
Sodium-Phosphate Cotransporter Proteins
0
Vitamin D
1406-16-2
FGF23 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM